Paraquat is a highly toxic herbicide used in some agricultural settings and has long been the subject of concern because of its potential effects on the nervous system. Its toxicity is closely linked to oxidative stress, a process in which unstable molecules known as reactive oxygen species damage proteins, lipids, DNA, and cellular membranes. Neurons are particularly sensitive to this kind of injury because they consume large amounts of oxygen, rely heavily on mitochondria for energy, and have limited capacity for regeneration. Paraquat can participate in redox cycling, repeatedly transferring electrons and generating reactive oxygen species. This can disrupt mitochondrial energy production and initiate inflammatory and degenerative pathways in vulnerable regions of the brain.

The research centers on the substantia nigra, a small but crucial structure located deep within the midbrain. This region contains dopamine-producing neurons that project to the striatum, helping regulate movement, motivation, and motor coordination. The gradual loss of these neurons is a defining feature of Parkinson’s disease. In experimental toxicology, damage to the substantia nigra is therefore used as an important indicator of Parkinsonian neurodegeneration. By examining the cytoarchitecture of this area, the investigators sought to determine whether paraquat alters the organization, density, and structural integrity of neurons and supporting tissue, and whether those changes differ between younger and older animals.

The study also evaluates neurobehaviour, providing a functional perspective that complements the microscopic analysis. Behavioural changes can reveal disturbances in motor coordination, exploratory activity, balance, muscle control, and general neurological performance before or alongside visible damage in the brain. In rodent models, these tests are valuable because the nervous system’s structural injury does not always translate immediately into an obvious clinical sign. A decline in movement or altered responses to the environment may indicate that dopamine circuits are no longer operating normally. Comparing these outcomes across age groups allows researchers to ask whether older animals show more pronounced impairment, whether younger animals possess greater resilience, or whether susceptibility changes in a more complex, exposure-dependent pattern.

One of the study’s central molecular targets is alpha-synuclein, a protein found naturally in nerve cells and involved in synaptic communication. Under healthy conditions, alpha-synuclein participates in the regulation of neurotransmitter release, but abnormal folding and accumulation of the protein are strongly associated with Parkinson’s disease and related disorders. Aggregated alpha-synuclein can interfere with cellular transport, mitochondrial function, and the disposal of damaged proteins. Oxidative stress may promote modifications that make the protein more likely to misfold or accumulate. By measuring alpha-synuclein levels after paraquat exposure, the researchers investigated whether the herbicide produces a molecular signature resembling mechanisms implicated in neurodegenerative disease.

Age may influence each of these processes. The aging brain generally experiences declining mitochondrial efficiency, weaker antioxidant defenses, changes in protein-clearance systems, and a greater tendency toward chronic, low-level inflammation. These shifts can reduce the capacity of neurons to neutralize reactive oxygen species or repair molecular damage. Dopaminergic neurons in the substantia nigra are already metabolically demanding and structurally vulnerable, making them especially sensitive to additional stress. Older animals may therefore cross a biological threshold more rapidly when exposed to paraquat. At the same time, younger brains are not automatically protected: developmental differences in metabolism, detoxification, neural connectivity, and antioxidant capacity may also shape the response to toxic chemicals.

The importance of the work lies in its attempt to connect three layers of evidence. Behavioural testing indicates whether exposure changes the animal’s neurological performance. Histological examination reveals how the substantia nigra is physically altered, including possible neuronal shrinkage, loss of cellular organization, or other signs of tissue injury. Alpha-synuclein analysis offers a biochemical view of whether paraquat affects a protein central to Parkinsonian pathology. When these measures move in the same direction, they provide a stronger argument that the observed effects are not limited to a temporary behavioural reaction or an isolated molecular change. Instead, they may reflect a coordinated process involving oxidative injury, structural degeneration, and impaired motor circuitry.

The findings are particularly relevant because they challenge the assumption that toxic exposure produces the same outcome in every individual. A fixed dose may represent very different biological burdens depending on age, metabolic state, exposure history, and the condition of the nervous system. This has consequences for laboratory research and public-health risk assessment. If aging increases susceptibility, studies using only young adult animals could underestimate the effects likely to occur in older populations. Conversely, if younger animals respond differently because of developmental biology, conclusions drawn from adult models may not apply to children or adolescents. Age-sensitive experimental design can therefore improve the interpretation of environmental neurotoxicity studies and help identify groups that require greater protection.

The results should not be interpreted as proof that paraquat exposure directly causes Parkinson’s disease in humans. Animal models reproduce selected features of complex human disorders, but they cannot capture every genetic, environmental, and clinical factor involved in disease development. Dose, route of exposure, duration, metabolism, and species-specific biology all influence the outcome. Nevertheless, evidence that paraquat affects movement, the substantia nigra, and alpha-synuclein in an age-dependent manner strengthens the rationale for continued investigation. It also underscores the need for careful handling of highly toxic chemicals, effective occupational safeguards, and rigorous monitoring of environmental exposure.

As research into Parkinson’s disease increasingly focuses on interactions between aging, environmental stressors, and protein misfolding, this study offers a useful framework for understanding how vulnerability develops. Its message is not simply that paraquat can harm the nervous system, but that the severity and character of that harm may depend on the biological age of the organism receiving the exposure. The combination of neurobehavioural assessment, anatomical analysis, and alpha-synuclein measurement provides a broad view of the toxic response. Future work will need to determine whether the observed changes are reversible, how long they persist, and whether antioxidant, anti-inflammatory, or protein-clearance interventions can protect the aging brain from paraquat-associated injury.

Subject of Research: Age-related susceptibility to paraquat-induced neurotoxicity in male Wistar rats, including neurobehaviour, substantia nigra cytoarchitecture, and alpha-synuclein levels.

Article Title: Age-related susceptibility to paraquat-induced neurotoxicity in male Wistar rats: effects on neurobehaviour, substantia nigra cytoarchitecture, and alpha-synuclein levels

Image Credits: AI Generated

Keywords: Paraquat, neurotoxicity, aging, male Wistar rats, substantia nigra, alpha-synuclein, oxidative stress, Parkinson’s disease, neurobehaviour, dopaminergic neurons

Parkinson’s disease, a progressive neurodegenerative disorder characterized primarily by motor dysfunction and dopaminergic neuron loss in the substantia nigra, remains a formidable challenge for translational neuroscience. While numerous rodent models have contributed foundational insights, the translational gap persists, underscoring the limitations of these models in fully recapitulating human pathophysiology. NHPs, sharing closer anatomical, genomic, and neurophysiological traits with humans, offer a superior model to simulate the complexity of PD, including its motor and non-motor symptomatology, disease progression, and response to pharmacological interventions.

Central to this advocacy is the recognition that advancing therapeutic strategies necessitates more than just model availability; it requires a comprehensive ecosystem integrating sophisticated tools, cutting-edge resources, and robust ethical frameworks. Investment in the development of novel NHP models that precisely mimic human neurodegenerative trajectories is critical. Such models must incorporate the heterogeneity of PD presentations, encompassing genetic variants, environmental factors, and age-related vulnerabilities, to provide a more holistic platform for investigating disease mechanisms and testing candidate therapies.

Furthermore, the ethical considerations surrounding NHP research command meticulous attention. The cognitive complexity and social behaviors of these primates impose a moral imperative to ensure their welfare and minimize suffering. This necessitates the establishment of stringent ethical standards that govern experimental design, housing conditions, and enrichment protocols. Equally important is transparency and active public engagement, fostering societal trust and understanding regarding the essential role of NHPs in addressing pressing neurological health challenges.

The implementation of an international research consortium dedicated to NHP-based neurodegenerative research emerges as a strategic solution to amplify collaborative efforts, optimize resource allocation, and standardize methodologies. Such a consortium would serve as a hub for consolidating expertise across neuroscience, primatology, genomics, and bioethics, facilitating the exchange of knowledge and accelerating discovery. Pooling data and biological resources internationally would mitigate duplication and foster rapid iteration of experimental paradigms aligned with clinical relevance.

Modern neuroimaging modalities and neurophysiological tools uniquely synergize with NHP research. Techniques such as positron emission tomography (PET), functional magnetic resonance imaging (fMRI), and in vivo electrophysiology in awake, behaving primates provide unprecedented resolution into disease mechanisms at cellular and circuit levels. Coupling these approaches with advanced molecular profiling and gene editing technologies further enhances the capacity of NHP models to interrogate pathogenesis and therapeutic impact with translational precision.

The ageing process itself is a complex, systemic phenomenon influenced by genetic, epigenetic, and environmental factors, culminating in increased susceptibility to neurodegenerative diseases like PD. NHPs naturally manifest ageing phenotypes that parallel those in humans, including cognitive decline, motor dysfunction, and neuropathological hallmarks, making them ideal subjects to dissect the interplay between ageing and neurodegeneration. This naturalistic aspect is challenging to emulate in short-lived rodent models, highlighting the irreplaceable value of primates in ageing research.

In addressing PD and ageing, the integration of multidisciplinary perspectives—from molecular biology and systems neuroscience to behavioral science and ethics—within the NHP research framework is paramount. This holistic approach ensures that findings extend beyond isolated observations to form cohesive mechanistic models, ultimately informing the development of targeted, patient-specific interventions.

Moreover, technological advances in gene editing, such as CRISPR/Cas9, have opened avenues to engineer precise genetic mutations associated with familial and sporadic forms of PD in NHPs. This capability allows for creating models that mirror the genetic underpinnings of human disease, enabling investigation into gene-environment interactions and the evaluation of gene therapy strategies within a physiologically relevant context.

Funding agencies and governmental bodies are called upon to prioritize resource allocation towards these endeavors, recognizing the pivotal role of NHP research in bridging experimental findings and clinical application. Long-term investments are imperative to sustain colony maintenance, develop infrastructure, and nurture training programs dedicated to NHP neuroscience, ensuring a robust pipeline of skilled investigators.

Public outreach and education are equally vital components of this proposed paradigm. Transparent communication about the scientific necessity, ethical safeguards, and prospective benefits of NHP research fosters informed societal discourse and supports continued engagement. By demystifying research practices and outcomes, the scientific community can galvanize public support and counteract potential misconceptions or opposition.

The envisioned international consortium would also facilitate the adoption and harmonization of standardized protocols, ensuring reproducibility and comparability of findings across laboratories and countries. This standardization is critical to build a cohesive body of evidence that can more effectively propel translational pipelines and regulatory approvals for novel therapeutics.

In the face of escalating global demographic shifts towards older populations, the urgency of confronting neurodegenerative disorders intensifies. NHP research, when strategically expanded and ethically conducted, offers an unparalleled platform to dissect disease complexity and accelerate therapeutic discovery, ultimately aiming to alleviate the immense societal and economic burdens imposed by PD and related ageing disorders.

The confluence of biological relevant modeling, cutting-edge technology, ethical stewardship, and international collaboration predicates a new era of neuroscience research. Harnessing the unique capabilities of non-human primates holds the promise to unlock the mechanistic enigmas of Parkinson’s disease and the ageing brain, translating into tangible clinical advances that preserve function and quality of life in aging populations worldwide.

Subject of Research: Neurodegenerative diseases, Parkinson’s disease, ageing, non-human primate models

Article Title: Position paper: leveraging non-human primate (NHP) specificities to accelerate Parkinson’s disease and ageing research.

Article References:
Bezard, E., Anderson, R.M., Badin, R.A. et al. Position paper: leveraging non-human primate (NHP) specificities to accelerate Parkinson’s disease and ageing research. npj Parkinsons Dis. 11, 227 (2025). https://doi.org/10.1038/s41531-025-01088-8

Image Credits: AI Generated